Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The purpose of this study is to determine whether \[225Ac\]Ac-PSMA-617 (AAA817), given for up to 6 cycles at a dose of 10 Megabecquerel (MBq) +/- 10%, plus androgen receptor pathway inhibitor (ARPI), improves the radiographic progression free survival (rPFS) compared to investigator's choice of standard of care (SOC) (ARPI change or taxane-based chemotherapy or \[177Lu\]Lu-PSMA-617 (AAA617)) in adult participants with PSMA-positive metastatic castration resistant prostate cancer (mCRPC) treated with another ARPI as last treatment and who have not been exposed to a taxane-containing chemotherapy in the mCRPC setting nor have received any prior PSMA-targeting radioligand therapy.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek co najmniej 18 lat
- •Potwierdzony histologicznie lub cytologicznie rak gruczołowy prostaty
- •Nowotwór dodatni w badaniu PET na PSMA
- •Wcześniejsze leczenie inhibitorem ARPI jako ostatnie leczenie przed włączeniem do badania
- •Brak wcześniejszego leczenia chemioterapią dla zaawansowanego raka prostaty opornego na kastrację
- •Ogólny stan zdrowia pozwalający na udział w badaniu (wynik ECOG 0-2)
- •Świadoma zgoda na udział w badaniu
✗ Disqualifies
- •Wcześniejsze leczenie radiofarmakami (np. Lu-177 PSMA, Ra-223)
- •Wcześniejsze leczenie inhibitorem PARP lub inną chemioterapią dla zaawansowanego raka prostaty opornego na kastrację
- •Napromienianie zewnętrzne w ciągu ostatnich 6 tygodni przed włączeniem do badania
- •Rak prostaty z komponentą neuroendokrynną (mieszana histologia)
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Maximum age
- 100 Years
- Last updated (source)
- July 24, 2026
- Sex
- Male only
Therapies / drugs in trial
Locations (88)
Urology Centers Of Alabama Pc
Homewood, United States
Stanford University Medical Center
Palo Alto, United States
Sansum Clinic
Santa Barbara, United States
Rocky Mountain Cancer Centers
Denver, United States
Florida Cancer Specialists
Fort Myers, United States
Baptist Health South
Miami, United States
AdventHealth
Orlando, United States
University Cancer and Blood Center LLC
Athens, United States
Northwestern University
Chicago, United States
Univ Of Iowa Hospitals And Clinics
Iowa City, United States
University of Kansas Hospital
Kansas City, United States
East Jefferson Hospital
Metairie, United States
Beth Israel Deaconess Med Center
Boston, United States
Dana Farber Cancer Institute
Boston, United States
Karmanos Cancer Institute
Detroit, United States
Wash U School of Medicine
St Louis, United States
Nebraska Cancer Specialists
Omaha, United States
Astera Cancer Center
East Brunswick, United States
New Jersey Urology LLC
Voorhees Township, United States
Bassett Medical Center
Cooperstown, United States
Weill Cornell Medicine NY-Presb
New York, United States
University of Rochester Medical Ctr
Rochester, United States
Associated Med Professionals of NY
Syracuse, United States
Montefiore Medical Center
The Bronx, United States
Central Ohio Urology Group
Gahanna, United States
MUSC Hollings Cancer Center
Charleston, United States
Carolina Urologic Research Center
Myrtle Beach, United States
Tennessee Oncology PLLC
Chattanooga, United States
Urology San Antonio
San Antonio, United States
Woodlands Cancer Institute American Oncology Partners
The Woodlands, United States
Swedish Medical Center
Seattle, United States
Northwest Medical Specialties
Tacoma, United States
Medical College of Wisconsin
Milwaukee, United States
Novartis Investigative Site
Darlinghurst, Australia
Novartis Investigative Site
Adelaide, Australia
Novartis Investigative Site
Malvern, Australia
Novartis Investigative Site
Murdoch, Australia
Novartis Investigative Site
Adelaide, Australia
Novartis Investigative Site
São Paulo, Brazil
Novartis Investigative Site
São Paulo, Brazil
Novartis Investigative Site
Fuzhou, China
Novartis Investigative Site
Guangzhou, China
Novartis Investigative Site
Guangzhou, China
Novartis Investigative Site
Wuhan, China
Novartis Investigative Site
Wuhan, China
Novartis Investigative Site
Nanjing, China
Novartis Investigative Site
Nanjing, China
Novartis Investigative Site
Shenyang, China
Novartis Investigative Site
Chengdu, China
Novartis Investigative Site
Hangzhou, China
Novartis Investigative Site
Beijing, China
Novartis Investigative Site
Beijing, China
Novartis Investigative Site
Guangzhou, China
Novartis Investigative Site
Shanghai, China
Novartis Investigative Site
Shanghai, China
Novartis Investigative Site
Shanghai, China
Novartis Investigative Site
Tianjin, China
Novartis Investigative Site
Tianjin, China
Novartis Investigative Site
Hong Kong, Hong Kong
Novartis Investigative Site
Gurgaon, India
Novartis Investigative Site
Bengaluru, India
Novartis Investigative Site
Mumbai, India
Novartis Investigative Site
Nagoya, Japan
Novartis Investigative Site
Sapporo, Japan
Novartis Investigative Site
Kobe, Japan
Novartis Investigative Site
Kobe, Japan
Novartis Investigative Site
Yokohama, Japan
Novartis Investigative Site
Chuo Ku, Japan
Novartis Investigative Site
Chiba, Japan
Novartis Investigative Site
Fukuoka, Japan
Novartis Investigative Site
Fukuoka, Japan
Novartis Investigative Site
Fukuoka, Japan
Novartis Investigative Site
Fukushima, Japan
Novartis Investigative Site
Hiroshima, Japan
Novartis Investigative Site
Kyoto, Japan
Novartis Investigative Site
Singapore, Singapore
Novartis Investigative Site
Singapore, Singapore
Novartis Investigative Site
Singapore, Singapore
Novartis Investigative Site
Seoul, South Korea
Novartis Investigative Site
Seoul, South Korea
Novartis Investigative Site
Seoul, South Korea
Novartis Investigative Site
Seoul, South Korea
Novartis Investigative Site
Seoul, South Korea
Novartis Investigative Site
Seoul, South Korea
Novartis Investigative Site
Kaohsiung City, Taiwan
Novartis Investigative Site
Taipei, Taiwan
Novartis Investigative Site
Taoyuan, Taiwan
Novartis Investigative Site
Sutton, United Kingdom
Trial contact
Novartis Pharmaceuticals
Novartis Pharmaceuticals
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/26/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.